Title:
SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
Document Type and Number:
WIPO Patent Application WO2006023356
Kind Code:
A3
Abstract:
The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
Inventors:
BOKVIST BENGT KRISTER (DE)
MAYER JOHN PHILIP (US)
ZHANG LIANSHAN (US)
ALSINA-FERNANDEZ JORGE (US)
VICK ANDREW MARK (US)
MAYER JOHN PHILIP (US)
ZHANG LIANSHAN (US)
ALSINA-FERNANDEZ JORGE (US)
VICK ANDREW MARK (US)
Application Number:
PCT/US2005/028520
Publication Date:
May 18, 2006
Filing Date:
August 11, 2005
Export Citation:
Assignee:
LILLY CO ELI (US)
BOKVIST BENGT KRISTER (DE)
MAYER JOHN PHILIP (US)
ZHANG LIANSHAN (US)
ALSINA-FERNANDEZ JORGE (US)
VICK ANDREW MARK (US)
BOKVIST BENGT KRISTER (DE)
MAYER JOHN PHILIP (US)
ZHANG LIANSHAN (US)
ALSINA-FERNANDEZ JORGE (US)
VICK ANDREW MARK (US)
International Classes:
A61K38/22; C07K14/435
Domestic Patent References:
| WO2001023420A2 | 2001-04-05 | |||
| WO2003058203A2 | 2003-07-17 | |||
| WO1998002453A2 | 1998-01-22 |
Foreign References:
| US20040058870A1 | 2004-03-25 |
Other References:
TSUTSUMI M ET AL: "A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes", DIABETES, NEW YORK, NY, US, vol. 51, no. 5, May 2002 (2002-05-01), pages 1453 - 1460, XP002348792, ISSN: 0012-1797
GOURLET PHILIPPE ET AL: "Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neural endopeptidase EC 3.4.24.11", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 54, 1997, pages 509 - 515, XP002971313, ISSN: 0006-2952
XIA MENGHAN ET AL: "Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 281, no. 2, 1997, pages 629 - 633, XP002358167, ISSN: 0022-3565
MORENO D ET AL: "Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 21, no. 10, October 2000 (2000-10-01), pages 1543 - 1549, XP002348791, ISSN: 0196-9781
DOYLE M E ET AL: "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 114, no. 2-3, 15 July 2003 (2003-07-15), pages 153 - 158, XP002349264, ISSN: 0167-0115
GOURLET PHILIPPE ET AL: "Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP-27, but not PACAP-38) degradation by the neural endopeptidase EC 3.4.24.11", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 54, 1997, pages 509 - 515, XP002971313, ISSN: 0006-2952
XIA MENGHAN ET AL: "Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 281, no. 2, 1997, pages 629 - 633, XP002358167, ISSN: 0022-3565
MORENO D ET AL: "Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC2 receptor", PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 21, no. 10, October 2000 (2000-10-01), pages 1543 - 1549, XP002348791, ISSN: 0196-9781
DOYLE M E ET AL: "The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 114, no. 2-3, 15 July 2003 (2003-07-15), pages 153 - 158, XP002349264, ISSN: 0167-0115
Download PDF: